S Kant Healthcare Limited

S Kant Healthcare Limited, established on March 18, 1996, is a public unlisted company headquartered in Mumbai, Maharashtra, India. It operates under the Corporate Identification Number (CIN) U24230MH1996PLC098246. The company is a subsidiary of the SK Group, a conglomerate with a legacy in the pharmaceutical industry dating back to 1932.

The authorized capital of S Kant Healthcare Limited is ₹10 million, with a paid-up capital of ₹9.8 million. As of the latest available data, the company employs approximately 540 professionals. The registered office is located at A/3, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Mumbai, Maharashtra 400018, India.

S Kant Healthcare Limited operates a state-of-the-art manufacturing facility in Vapi, Gujarat, India. This EU-GMP certified plant spans 11 acres (approximately 45,000 square meters) and is equipped with dedicated buildings for the production of finished formulations, active pharmaceutical ingredients (APIs), metallic stearates, and herbal extracts. The facility is strategically located with easy access by air, sea, road, and rail, facilitating efficient distribution to both domestic and international markets.

The leadership team at S Kant Healthcare Limited comprises:

• Bharat Nemchand Shah: Director
• Samir Jayantilal Shah: Director
• Ritesh Bipin Shah: Director
• Rohan Mahesh Shah: Director
• Gaurav Satish Shah: Director
• Mahesh Harishchandra Kolambe: Director

These individuals bring a wealth of experience and strategic vision to the company, driving its growth and global expansion.

S Kant Healthcare Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds EU-GMP certification, ensuring compliance with stringent European standards. Additionally, the plant has received approvals from various Ministries of Health, such as Ghana-FDA, Kenya-P&PB, Nigeria-NAFDAC, and Uganda-NDA, facilitating market access in these regions.

S Kant Healthcare Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 80 countries, with a dedicated operational presence in regions like East Africa. The manufacturing facility's WHO prequalification enhances access to these markets, enabling the company to supply essential medicines to underserved populations.

S Kant Healthcare Limited demonstrates a diversified geographic strategy, mitigating concentration risk by operating in over 80 countries. The company's strategic direction focuses on expanding its global presence while maintaining a strong foothold in emerging markets. This approach ensures a balanced portfolio and resilience against regional market fluctuations.

S Kant Healthcare Limited's manufacturing facility is registered with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the approval of its generic formulations in the U.S. market. The facility has undergone FDA inspections, receiving favorable outcomes, which underscores its commitment to quality and regulatory compliance.

The manufacturing facility holds both WHO prequalification and EU-GMP certifications, affirming its adherence to international quality standards. These accreditations enable S Kant Healthcare Limited to supply essential medicines to a global clientele, including international organizations and government agencies.

S Kant Healthcare Limited's manufacturing facility is licensed by the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory requirements. The company has obtained approvals from various state drug controllers and holds export No Objection Certificates (NOCs), facilitating the export of its products to numerous countries.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to S Kant Healthcare Limited by regulatory authorities. This absence suggests a strong compliance record and adherence to regulatory standards.

S Kant Healthcare Limited operates in a competitive landscape, with key competitors in overlapping therapeutic categories such as antimalarial, antifungal, and antibiotic formulations. The company's market share in these categories positions it favorably, with a particularly strong presence in antimalarial and antiparasitic products. A head-to-head analysis reveals that S Kant's product portfolio and manufacturing capabilities provide a competitive edge in terms of quality, supply chain reliability, and regulatory compliance.

S Kant Healthcare Limited's unique strengths include its backward integration within the SK Group, which ensures a consistent supply of APIs and finished formulations. The company's EU-GMP certified manufacturing facility and WHO prequalification further distinguish it in the market. Additionally, S Kant's extensive product portfolio across multiple therapeutic categories and its presence in over 80 countries underscore its global reach and commitment to quality.

S Kant Healthcare Limited's current strategic direction focuses on expanding its global footprint through the supply of generic pharmaceuticals, with an emphasis on essential medicines. The company's future outlook includes exploring opportunities in specialty pharmaceuticals and Contract Development and Manufacturing Organization (CDMO) services, leveraging its manufacturing capabilities and regulatory accreditations to serve a broader range of clients.

S Kant Healthcare Limited has a commendable track record in manufacturing and exporting pharmaceutical products, with a total export value of $35.0 million USD and 946 shipments across 12 products in 6 therapeutic categories. The company's portfolio concentration, with the top 5 products accounting for 79.4% of exports, indicates a focused approach. Reliability indicators include its EU-GMP certification, WHO prequalification, and approvals from various Ministries of Health, reflecting consistent quality and compliance.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the facility's registration status with the U.S. FDA to ensure compliance with U.S. standards.

• WHO-GMP Certification: Verify the facility's WHO prequalification to ensure adherence to international quality standards.

• EU GMP Certification: Check for EU-GMP certification to confirm compliance with European manufacturing standards.

• ISO Certifications: Review ISO certifications, such as ISO 14001:2004 and OHSAS 18001:2007, to assess environmental and occupational health and safety management systems.

These certifications can typically be verified through the company's official website or by contacting the relevant regulatory bodies.

Importers should undertake the following steps to ensure a thorough evaluation of S Kant Healthcare Limited:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Manufacturing Capabilities: Evaluate the facility's capacity, technological capabilities, and compliance with international standards.

• Review Financial Stability: Analyze financial statements to assess the company's financial health and stability.

• Evaluate Supply Chain Reliability: Assess the company's logistics and distribution capabilities to ensure timely delivery.

• Check Compliance History: Review any past regulatory actions, such as warning letters or import alerts, to gauge compliance history.

Red flags to watch for include expired certifications, unresolved regulatory issues, and inconsistent product quality. Recommended pre-order checks involve requesting recent inspection reports, quality control documentation, and references from existing clients.